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Introduction
The transition from benign tumors to invasive, meta-
static cancer cells involves changes in the extracellular
matrix environment, cell motility, and cell-cell adhesion.
Because cell-cell–adhesion molecules are dynamically
regulated during human carcinogenesis, they have been
implicated in tumorigenesis, especially during the later
stages of tumor progression—that is, tumor-cell invasion
and metastasis (Thiery 1996). In this review, we focus
on the evidence from genetics and cell-culture studies
that support a functional role of E-cadherin/catenin ad-
hesion complexes in carcinogenesis. We discuss both the
potential downstream signals that changes in E-cad-
herin–mediated cell-cell adhesion may elicit during tu-
morigenesis and a possible connection between E-cad-
herin function and Wnt signaling.
Many studies have implicated E-cadherin in the de-
velopment of human cancers. The great interest in this
protein may, in part, reflect its role as the major cell-
cell–adhesion molecule in epithelial cells, the cell type
from which ∼80% of human cancers derive. Epithelial
cells are tightly interconnected through a junctional
complex, consisting of tight junctions, adherens junc-
tions, and desmosomes, structures that are intimately
associated with the actin and intermediate cytoskeletal
filament systems. E-cadherin mediates Ca2-dependent
homophilic interactions, as the major adhesion receptor
in adherens junctions. This function is essential both to
establish and to maintain cell-cell junctions (reviewed in
Takeichi 1995; Aberle et al. 1996), and mice deficient
for E-cadherin die in utero, because of defective for-
mation of the first epithelium, the trophectoderm (Larue
et al. 1994; Riethmacher et al. 1995).
Intracellularly, E-cadherin is linked to the catenins
(a-, b-, and g-catenin/plakoglobin), which connect E-
cadherin to the actin cytoskeleton (fig. 1). Failure either
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to assemble the E-cadherin/catenin complex or to prop-
erly connect to the actin cytoskeleton results in the loss
of cell adhesion. Hence, mutations in numerous genes
other than CDH1, which encodes the human E-cad-
herin, may also affect cell adhesion. Finally, although
this view is supported mainly by circumstantial evidence,
E-cadherin–mediated cell adhesion may also participate
in the transduction of transmembrane signals that reg-
ulate gene expression and cell fate (reviewed in Huber
et al. 1996; Gumbiner 1997; Bullions and Levine 1998).
Like the classical cadherins, desmosomal cadherins
have been implicated in human disease. Dsg1 (desmo-
glein I), which is a major adhesive component in supra-
basal epidermal and lingual desmosomes, is the antigenic
target of autoantibodies found in patients with the blis-
tering disease pemphigus foliaceus (Eyre and Stanley
1987). Another desmoglein, Dsg3, is recognized by sera
from patients with a more severe form of this disease,
known as “pemphigus vulgaris” (Amagai et al. 1991).
E-Cadherin Function Is Suppressed during
Carcinogenesis
In recent years, a large number of studies have re-
vealed that E-cadherin function is frequently inactivated
during the development of human carcinomas, including
those of the breast, colon, prostate, stomach, liver,
esophagus, skin, kidney, and lung (for a more extensive
list, see Birchmeier and Behrens 1994; Bracke et al.
1996). Abrogation of E-cadherin function may occur by
any of several mechanisms, but it frequently involves
deletion or mutation of the CDH1 gene (reviewed in
Birchmeier and Behrens 1994; Bracke et al. 1996). Re-
markably, germ-line mutations inCDH1 have been iden-
tified in cases of familial gastric cancers, indicating that
aberrations in this gene are sufficient to predispose to
the development of malignant cancer (Guilford et al.
1998). Furthermore, changes in the expression of pro-
teins that are part of the E-cadherin–adhesion complex
have also been found to impair E-cadherin–mediated
cell-cell adhesion. For example, down-regulation of a-
catenin or b-catenin expression (De Leeuw et al. 1997),
as well as the expression of mutant forms of either a-
catenin (Bullions et al. 1997) or b-catenin (Oyama et al.
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Figure 1 Schematic representation of the E-cadherin adhesion complex (for details, see the text)
1994), sometimes coincides with malignant transfor-
mation. Moreover, mutations of the b-catenin gene are
frequently found in colon cancers (Sparks et al. 1998).
However, it remains to be determined, for each type of
cancer, how changes in the expression of either a-catenin
or b-catenin affect E-cadherin function.
In addition to deletions and mutations, several other
mechanisms have been identified that directly affect E-
cadherin expression and function. For example, chro-
matin rearrangement, hypermethylation, and loss of
transcription-factor binding frequently coincide with
suppression of E-cadherin–promoter activity in invasive
carcinoma cells (Yoshiura et al. 1995; Hennig et al.
1996). Notably, in some tumor types, inactivation of the
E-cadherin gene by hypermethylation appears to be a
major mechanism—for example, in papillary thyroid
carcinoma, where hypermethylation of the E-cadherin
promoter has been found in 83% of the cases examined
(Graff et al. 1998).
Other epigenetic events that are required for E-cad-
herin function during normal developmental processes
may also be involved in the misregulation of E-cadherin
during tumorigenesis. For example, E-cadherin function
can be affected by the Rho family of GTPases (Braga et
al. 1997; Jou and Nelson 1998), growth factor–receptor
signaling (Hoschuetzky et al. 1994; Shibamoto et al.
1994), integrin-linked kinase (Novak et al. 1998), and
matrix metalloproteases (Lochter et al. 1997).
Because decreased E-cadherin function generally cor-
relates with dedifferentiation, infiltrative tumor growth,
and metastasis, E-cadherin has been proposed as a
marker to indicate poor prognosis (reviewed in Birch-
meier and Behrens 1994; Bracke et al. 1996). Although
E-cadherin is not the only cadherin that is expressed in
epithelial cells, few others have been implicated in can-
cer. One exception is H-cadherin, which has been found
to be lost during the development of breast cancer (Lee
1996).
E-Cadherin Suppresses Tumor-Cell Invasion
Because the loss of E-cadherin function so closely par-
allels carcinogenesis, many groups have sought to elu-
cidate the role of E-cadherin in tumor progression. In
various cell-culture systems, the reestablishment of a
functional cadherin/catenin complex causes invasive tu-
mor-cell lines to revert to a benign, epithelial cellular
phenotype (reviewed in Frixen et al. 1991; Vleminckx
et al. 1991; Birchmeier and Behrens 1994; Bracke et al.
1996), clearly demonstrating that E-cadherin can sup-
press the overt features of advanced tumor progression.
However, it has remained unresolved whether the loss
of E-cadherin–mediated cell adhesion is a prerequisite
for tumor progression or is a consequence of dediffer-
entiation during tumor progression in vivo. Using a
transgenic mouse model of pancreatic b-cell tumorigen-
esis (Rip1Tag2; Hanahan 1985), our laboratories have
recently addressed this question and have demonstrated
that the loss of E-cadherin–mediated cell-cell adhesion
is causally involved in the transition from well-differ-
entiated adenoma to invasive carcinoma (Perl et al.
1998; see sidebar). However, the mere loss of E-cad-
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Rip1Tag2—A Versatile Transgenic Mouse Model
for Tumor Progression
Rip1Tag2, a prototype of the mouse models for tumorigenesis,
is a transgenic mouse line that expresses SV 40 T antigen under
the control of the insulin promoter in the b-cells of the pan-
creatic islets of Langerhans (Hanahan 1985). These mice re-
producibly develop b-cell tumors in a multistage tumorigenesis
pathway involving islet hyperplasia (∼70% of all islets), the
formation of new blood vessels (angiogenesis; ∼20%), well-
differentiated, benign tumors (adenomas; ∼2%), and, finally,
dedifferentiated, invasive tumors (carcinomas; ∼0.5%). Metas-
tases are usually not found in these mice, probably because they
succumb to hypoglycemia (i.e., they die before metastasis can
happen), with increased tumor mass.
The Rip1Tag2 tumor model has proved a powerful tool with
which to study the molecular mechanism of multistage tumor
development, including tumor-cell proliferation, apoptosis, and
angiogenesis. We have employed the Rip1Tag2 transgenic
mouse model to investigate molecular mechanisms of tumor
invasion and metastasis. As in the progression of many epithe-
lial cancers, E-cadherin is lost during the transition from well-
differentiated adenoma to invasive carcinoma in Rip1Tag2
transgenic mice (Perl et al. 1998). To assess whether loss of E-
cadherin–mediated cell adhesion is a cause or a consequence
of tumor progression in vivo, we have intercrossed Rip1Tag2
transgenic mice with transgenic mice that express either wild-
type E-cadherin or a dominant-negative form of E-cadherin,
specifically in the pancreatic b-cells (Perl et al. 1998). Main-
tenance of E-cadherin expression during b-cell tumorigenesis
results in arrest of tumor development at the adenoma stage.
In contrast, expression of a dominant-negative E-cadherin in-
duces early invasion and metastasis. The results demonstrate
that loss of E-cadherin–mediated cell adhesion is one rate-lim-
iting step in the progression from adenoma to carcinoma in
vivo.
herin–mediated adhesion appears not to be sufficient for
the tumor cells to penetrate the basal lamina and invade
the surrounding tissue (Perl et al. 1998). Thus, we spec-
ulate that E-cadherin may also convey signals that ac-
tively induce tumor-cell invasion.
b-Catenin—A Potential Mediator of E-
Cadherin–Mediated Downstream Signals
b-Catenin is a multifunctional protein that performs
many functions in a cell—for example, in E-cad-
herin–mediated adhesion, in membrane extensions, and
in Wnt signaling (reviewed in Barth et al. 1997; Gum-
biner 1997). b-Catenin that is not sequestered in the E-
cadherin cell-adhesion complex is rapidly phosphoryl-
ated by glycogen synthetase kinase-3b (GSK-3b) in the
adenomatous polyposis coli (APC)/GSK-3b complex and
subsequently is degraded by the ubiquitin-proteasome
pathway (fig. 2). Several mechanisms are able to block
degradation of b-catenin, culminating in an accumula-
tion of free b-catenin in the cytoplasm; these mechanisms
include mutations in the phosphorylation sites that are
important for b-catenin’s degradation, mutations in APC
that render it nonfunctional, as well as activation of
GSK-3b activity, which blocks signaling by Wnt. Fol-
lowing translocation into the nucleus, b-catenin binds
to members of the TCF/LEF-1 family of transcription
factors, possibly modulating the expression of target
genes (reviewed in Behrens et al. 1996; Huber et al.
1996; Molenaar et al. 1996; Korinek et al. 1997; Morin
et al. 1997; Rubinfeld et al. 1997; Gumbiner 1998).
Several lines of evidence indicate that E-cadherin-me-
diated signaling could feed into the b-catenin/TCF/LEF-
1 pathway. Although b-catenin clearly performs distinct
functions in E-cadherin-mediated cell adhesion and in
Wnt signaling (Orsulic and Peifer 1996; Sanson et al.
1996), there appears to be some cross-talk between the
adhesive and the signaling pathways. Thus, the expres-
sion of excess cadherin interferes with Wnt signaling by
competing for b-catenin binding (Fagotto et al. 1996;
Sanson et al. 1996). It remains to be determined whether
the opposite situation occurs—that is, whether loss of
cadherin leads to the accumulation of b-catenin free to
bind TCF/LEF-1 and to modulate transcription (fig. 2).
However, recent experimental evidence supports this
possibility: mouse ES cells that lack functional E-cad-
herin genes (i.e., cells that are /) express LEF-1
mRNA, whereas wild-type ES cells (i.e., those that are
/) do not (Huber et al. 1996). Moreover, forced ex-
pression of E-cadherin in E-cadherin–deficient ES cells
leads to the repression of LEF-1. In return, LEF-1/b-
catenin is able to bind to the E-cadherin promoter and
to suppress E-cadherin expression (Huber et al. 1996).
These results support a connection between E-cadherin
function and b-catenin/TCF transcriptional activity, but
it remains uncertain whether this link is physiologically
relevant and whether the connection is direct or indirect.
More-detailed information regarding the roles of APC
and b-catenin during carcinogenesis recently has been
obtained from investigation of the function of these pro-
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Figure 2 Schematic representation of the possible link between E-cadherin–mediated cell-cell adhesion and the Wnt-signaling pathway
(for details, see the text). Question marks indicate future goals in cancer research: whether E-cadherin competes directly with the Wnt/b-
catenin–signaling pathway; whether it affects TCF/b-catenin signaling, independent of the Wnt-signaling pathway; and what additional TCF/
b-catenin target genes are relevant to tumorigenesis.
teins in the etiology of colon carcinoma and melanoma
(Korinek et al. 1997; Morin et al. 1997; Rubinfeld et
al. 1997). Mutations of either b-catenin or APC have
the same effect on b-catenin stability and TCF transac-
tivation, consistent with the notion that both genes act
in the same signaling pathway (Sparks et al. 1998). These
results raise the interesting possibility that b-catenin can
act as an oncogene, a notion that Wong et al. (1998)
have tested recently by expressing a mutated, protease-
resistant form of b-catenin in the small intestine of mice.
Although an increase in proliferation and apoptosis of
crypt cells was observed, b-catenin appeared not to be
sufficient to induce tumor formation (Wong et al. 1998).
The recent identification of c-MYC as a direct target
gene of TCF/b-catenin–mediated transactivation has
added new, important information as to how TCF/b-
catenin signaling may affect tumor-cell proliferation (He
et al. 1998). By means of serial analysis of gene ex-
pression (SAGE), c-MYC was identified as a target for
APC function in colon cells. Cells without a functional
APC gene exhibited high c-MYC expression, whereas
reexpression of a functional APC protein resulted in
down-regulation of c-MYC. The findings demonstrate
that c-MYC activation is a direct consequence of
APC loss and, therefore, could induce tumor-cell
proliferation.
Finally, it is conceivable that the transcriptional ac-
tivity of each TCF/LEF-1 family member will depend on
both the particular family member in whom the gene is
expressed and the cellular context. Thus, each TCF may
modulate different target genes in different cell types or
in varying combinations with other transcription factors
(Hsu et al. 1998).
The notion that cadherin-mediated cell adhesion
might transduce signals to the nucleus raises the intrigu-
ing possibility that changes in cell adhesion may mod-
ulate gene expression and, thus, cell fate. Indeed, the
experimental findings that gain of E-cadherin function
is able to block the transition from adenoma to carci-
noma and that loss of cadherin-mediated cell adhesion
can induce tumor-cell invasion (Perl et al. 1998) indicate
that cell adhesion-mediated signals may govern pro-
gression from adenoma to carcinoma during carcino-
genesis. Whether similar signals may govern complete
genetic programs during nonpathological conditions,
such as mesenchymal-epithelial conversion during em-
bryonic development, remains unclear.
The frequent loss of E-cadherin–mediated cell adhe-
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sion in epithelial cancers, together with its function as
a repressor of tumor progression, nominates E-cadherin
as an important tumor-suppressor gene. However, de-
spite the significant progress in the field, the exact mo-
lecular mechanisms underlying E-cadherin–mediated tu-
mor suppression remains unknown. Future research will
have to address whether E-cadherin exerts its tumor-
suppressing function through its cell-cell adhesion ca-
pabilities or through potential downstream signaling
pathways.
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